Kristin Mekeel
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 25 | 2025 | 708 | 2.970 |
Why?
| | Liver Transplantation | 22 | 2025 | 871 | 2.260 |
Why?
| | Organ Transplantation | 7 | 2024 | 250 | 1.350 |
Why?
| | Liver Diseases | 8 | 2015 | 315 | 1.310 |
Why?
| | Pancreas Transplantation | 7 | 2011 | 75 | 1.260 |
Why?
| | Laparoscopy | 11 | 2016 | 466 | 1.170 |
Why?
| | Graft Survival | 11 | 2025 | 535 | 1.130 |
Why?
| | Nephrectomy | 6 | 2020 | 169 | 1.130 |
Why?
| | Hepatectomy | 8 | 2015 | 251 | 1.080 |
Why?
| | Tissue Donors | 9 | 2025 | 425 | 1.060 |
Why?
| | Kidney Failure, Chronic | 7 | 2021 | 570 | 1.030 |
Why?
| | Postoperative Complications | 16 | 2024 | 2654 | 0.970 |
Why?
| | Liver Neoplasms | 7 | 2022 | 786 | 0.950 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2022 | 362 | 0.950 |
Why?
| | Liver Cirrhosis | 4 | 2022 | 316 | 0.940 |
Why?
| | Living Donors | 7 | 2018 | 295 | 0.910 |
Why?
| | Kidney | 5 | 2021 | 1468 | 0.750 |
Why?
| | Hepatic Stellate Cells | 1 | 2020 | 13 | 0.670 |
Why?
| | Renal Nutcracker Syndrome | 1 | 2020 | 9 | 0.650 |
Why?
| | Pain, Postoperative | 1 | 2022 | 265 | 0.630 |
Why?
| | Bile Ducts, Intrahepatic | 4 | 2013 | 78 | 0.620 |
Why?
| | Students, Medical | 1 | 2023 | 348 | 0.600 |
Why?
| | Waiting Lists | 5 | 2020 | 266 | 0.600 |
Why?
| | Cholangiocarcinoma | 4 | 2013 | 104 | 0.580 |
Why?
| | Bile Duct Neoplasms | 4 | 2013 | 124 | 0.570 |
Why?
| | Hepatitis C | 5 | 2025 | 271 | 0.560 |
Why?
| | Cysts | 2 | 2008 | 113 | 0.550 |
Why?
| | Renal Artery | 2 | 2015 | 37 | 0.540 |
Why?
| | Graft Rejection | 7 | 2015 | 624 | 0.520 |
Why?
| | Blood Vessel Prosthesis Implantation | 3 | 2013 | 202 | 0.520 |
Why?
| | Diabetes Mellitus | 4 | 2021 | 1040 | 0.510 |
Why?
| | Hepatitis B | 1 | 2016 | 70 | 0.490 |
Why?
| | Tissue and Organ Harvesting | 1 | 2015 | 70 | 0.470 |
Why?
| | Tissue and Organ Procurement | 4 | 2024 | 321 | 0.450 |
Why?
| | Humans | 78 | 2025 | 137585 | 0.450 |
Why?
| | Vascular Diseases | 2 | 2015 | 243 | 0.440 |
Why?
| | Transplant Recipients | 4 | 2025 | 184 | 0.440 |
Why?
| | Middle Aged | 36 | 2025 | 33479 | 0.430 |
Why?
| | Retrospective Studies | 26 | 2024 | 15657 | 0.430 |
Why?
| | Salvage Therapy | 1 | 2015 | 142 | 0.430 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1000 | 0.420 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2023 | 279 | 0.420 |
Why?
| | Adult | 35 | 2025 | 37929 | 0.410 |
Why?
| | Internship and Residency | 1 | 2023 | 1147 | 0.410 |
Why?
| | Operating Rooms | 2 | 2024 | 123 | 0.380 |
Why?
| | Pancreatectomy | 2 | 2011 | 253 | 0.370 |
Why?
| | Vena Cava, Inferior | 2 | 2013 | 71 | 0.370 |
Why?
| | Viremia | 2 | 2025 | 138 | 0.350 |
Why?
| | Sphincterotomy, Transduodenal | 1 | 2011 | 1 | 0.350 |
Why?
| | Hernia, Ventral | 2 | 2009 | 24 | 0.350 |
Why?
| | Biliary Tract Diseases | 2 | 2012 | 39 | 0.350 |
Why?
| | Ampulla of Vater | 1 | 2011 | 42 | 0.340 |
Why?
| | Treatment Outcome | 24 | 2021 | 10811 | 0.340 |
Why?
| | Hepacivirus | 2 | 2025 | 261 | 0.330 |
Why?
| | Follow-Up Studies | 14 | 2025 | 5131 | 0.320 |
Why?
| | Female | 41 | 2025 | 73304 | 0.320 |
Why?
| | Spleen | 1 | 2011 | 514 | 0.310 |
Why?
| | Rhabdomyolysis | 1 | 2009 | 21 | 0.310 |
Why?
| | Ascites | 1 | 2009 | 46 | 0.300 |
Why?
| | Male | 38 | 2025 | 67762 | 0.300 |
Why?
| | Pancreas | 1 | 2011 | 329 | 0.300 |
Why?
| | Peritonitis | 1 | 2009 | 84 | 0.290 |
Why?
| | Echinococcosis, Hepatic | 1 | 2007 | 1 | 0.290 |
Why?
| | Gallbladder Neoplasms | 1 | 2007 | 23 | 0.270 |
Why?
| | Aged | 18 | 2025 | 23961 | 0.270 |
Why?
| | Risk Assessment | 2 | 2016 | 3457 | 0.270 |
Why?
| | Cholecystectomy | 1 | 2007 | 62 | 0.270 |
Why?
| | Bacterial Infections | 1 | 2009 | 250 | 0.260 |
Why?
| | Reoperation | 3 | 2020 | 573 | 0.250 |
Why?
| | Stents | 2 | 2012 | 527 | 0.250 |
Why?
| | Intraoperative Complications | 1 | 2007 | 138 | 0.250 |
Why?
| | Morbidity | 2 | 2023 | 324 | 0.240 |
Why?
| | Mucormycosis | 1 | 2005 | 22 | 0.240 |
Why?
| | Portal Vein | 4 | 2016 | 120 | 0.220 |
Why?
| | Liver Failure | 2 | 2017 | 94 | 0.220 |
Why?
| | Beluga Whale | 1 | 2024 | 1 | 0.220 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2005 | 140 | 0.220 |
Why?
| | Organ Preservation | 1 | 2024 | 102 | 0.210 |
Why?
| | Incidence | 3 | 2016 | 2804 | 0.210 |
Why?
| | Coinfection | 1 | 2025 | 137 | 0.210 |
Why?
| | Pancreatic Neoplasms | 1 | 2011 | 938 | 0.210 |
Why?
| | Perfusion | 1 | 2024 | 213 | 0.200 |
Why?
| | Materia Medica | 1 | 2023 | 1 | 0.200 |
Why?
| | Anemia, Sickle Cell | 1 | 2007 | 270 | 0.200 |
Why?
| | Body Weight | 1 | 2007 | 985 | 0.190 |
Why?
| | Morphine Derivatives | 1 | 2022 | 17 | 0.190 |
Why?
| | Tablets | 1 | 2022 | 40 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 67 | 0.190 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 137 | 0.180 |
Why?
| | Acute Kidney Injury | 1 | 2009 | 815 | 0.180 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5778 | 0.180 |
Why?
| | Antiviral Agents | 4 | 2025 | 744 | 0.180 |
Why?
| | Time Factors | 9 | 2023 | 6828 | 0.170 |
Why?
| | Glomerular Filtration Rate | 3 | 2015 | 746 | 0.170 |
Why?
| | Consent Forms | 1 | 2020 | 11 | 0.170 |
Why?
| | Length of Stay | 4 | 2015 | 1215 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2022 | 245 | 0.160 |
Why?
| | Endoscopy, Digestive System | 2 | 2012 | 136 | 0.160 |
Why?
| | Creatinine | 4 | 2015 | 499 | 0.160 |
Why?
| | Pancreaticoduodenectomy | 3 | 2016 | 164 | 0.150 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 238 | 0.150 |
Why?
| | Recombination, Genetic | 2 | 1997 | 204 | 0.150 |
Why?
| | Prognosis | 4 | 2025 | 4030 | 0.150 |
Why?
| | Patient Selection | 3 | 2014 | 696 | 0.150 |
Why?
| | Vaccination | 2 | 2024 | 1381 | 0.150 |
Why?
| | Mycophenolic Acid | 2 | 2010 | 117 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 306 | 0.150 |
Why?
| | Leadership | 1 | 2022 | 388 | 0.140 |
Why?
| | Survival Analysis | 4 | 2010 | 1325 | 0.140 |
Why?
| | Gallbladder Diseases | 2 | 2007 | 12 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 7 | 2016 | 2691 | 0.140 |
Why?
| | Renal Dialysis | 1 | 2021 | 435 | 0.130 |
Why?
| | Risk Factors | 8 | 2025 | 10388 | 0.130 |
Why?
| | Granuloma, Plasma Cell | 1 | 2016 | 13 | 0.130 |
Why?
| | Antibodies, Monoclonal | 5 | 2010 | 1430 | 0.130 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1114 | 0.130 |
Why?
| | Recurrence | 5 | 2018 | 1060 | 0.130 |
Why?
| | Hypertension, Portal | 2 | 2007 | 64 | 0.130 |
Why?
| | Iliac Artery | 2 | 2015 | 55 | 0.130 |
Why?
| | Duodenal Neoplasms | 1 | 2016 | 23 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 1999 | 528 | 0.130 |
Why?
| | Fatal Outcome | 2 | 2009 | 303 | 0.130 |
Why?
| | Antilymphocyte Serum | 3 | 2010 | 66 | 0.120 |
Why?
| | Hyperglycemia | 2 | 2010 | 347 | 0.120 |
Why?
| | Antibodies, Neoplasm | 3 | 2010 | 34 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1329 | 0.120 |
Why?
| | Survival Rate | 3 | 2016 | 1972 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1509 | 0.120 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2015 | 6 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2015 | 7635 | 0.120 |
Why?
| | Liver | 2 | 2022 | 1943 | 0.120 |
Why?
| | Registries | 2 | 2021 | 2035 | 0.120 |
Why?
| | Immunosuppressive Agents | 6 | 2010 | 890 | 0.110 |
Why?
| | United States | 5 | 2024 | 14841 | 0.110 |
Why?
| | Donor Selection | 1 | 2015 | 77 | 0.110 |
Why?
| | Delayed Graft Function | 2 | 2018 | 33 | 0.110 |
Why?
| | Family | 2 | 2017 | 671 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2015 | 160 | 0.110 |
Why?
| | Electronic Health Records | 1 | 2022 | 1069 | 0.110 |
Why?
| | California | 1 | 2015 | 431 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2022 | 1208 | 0.110 |
Why?
| | Insulin | 3 | 2010 | 2409 | 0.110 |
Why?
| | Regression Analysis | 2 | 2014 | 1024 | 0.110 |
Why?
| | Quality Improvement | 1 | 2022 | 1178 | 0.100 |
Why?
| | Child | 7 | 2020 | 21935 | 0.100 |
Why?
| | Geography | 1 | 2014 | 200 | 0.100 |
Why?
| | Pregnancy Trimester, Second | 1 | 2013 | 80 | 0.100 |
Why?
| | Global Health | 1 | 2016 | 386 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1313 | 0.100 |
Why?
| | Pancreatic Ducts | 2 | 2011 | 85 | 0.100 |
Why?
| | Young Adult | 7 | 2023 | 13209 | 0.100 |
Why?
| | Surgical Wound Infection | 4 | 2009 | 307 | 0.100 |
Why?
| | End Stage Liver Disease | 1 | 2014 | 82 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2018 | 754 | 0.090 |
Why?
| | Hepatocytes | 2 | 2023 | 220 | 0.090 |
Why?
| | Contraindications | 1 | 2011 | 90 | 0.090 |
Why?
| | Splenectomy | 1 | 2011 | 62 | 0.090 |
Why?
| | Aspartate Aminotransferases | 2 | 2012 | 90 | 0.090 |
Why?
| | Bilirubin | 2 | 2012 | 97 | 0.090 |
Why?
| | Surgical Mesh | 2 | 2009 | 47 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2015 | 911 | 0.090 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1291 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 268 | 0.080 |
Why?
| | Cholestasis | 2 | 2012 | 235 | 0.080 |
Why?
| | HIV Infections | 1 | 2025 | 2836 | 0.080 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 245 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4295 | 0.080 |
Why?
| | C-Peptide | 1 | 2010 | 163 | 0.080 |
Why?
| | Sclerosis | 1 | 2009 | 13 | 0.080 |
Why?
| | Hemobilia | 1 | 2009 | 1 | 0.080 |
Why?
| | Atrophy | 1 | 2010 | 184 | 0.080 |
Why?
| | Paracentesis | 1 | 2009 | 14 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 198 | 0.080 |
Why?
| | Kidney Tubules | 1 | 2010 | 117 | 0.080 |
Why?
| | Physical Endurance | 1 | 2010 | 275 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.080 |
Why?
| | Inpatients | 2 | 2010 | 500 | 0.080 |
Why?
| | Boronic Acids | 1 | 2009 | 37 | 0.070 |
Why?
| | Drug Overdose | 1 | 2013 | 347 | 0.070 |
Why?
| | Intestinal Obstruction | 1 | 2009 | 51 | 0.070 |
Why?
| | Surgical Stapling | 1 | 2008 | 15 | 0.070 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2012 | 262 | 0.070 |
Why?
| | Hepatomegaly | 1 | 2008 | 4 | 0.070 |
Why?
| | Isoantibodies | 1 | 2009 | 60 | 0.070 |
Why?
| | Protease Inhibitors | 1 | 2009 | 107 | 0.070 |
Why?
| | Cadaver | 1 | 2009 | 296 | 0.070 |
Why?
| | Pyrazines | 1 | 2009 | 90 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 83 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2008 | 114 | 0.070 |
Why?
| | Pancreatitis | 1 | 2009 | 134 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2009 | 145 | 0.070 |
Why?
| | Pancreatic Diseases | 1 | 2008 | 72 | 0.070 |
Why?
| | Adolescent | 5 | 2016 | 21513 | 0.070 |
Why?
| | HLA Antigens | 1 | 2009 | 240 | 0.070 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2007 | 18 | 0.070 |
Why?
| | Fibrosis | 1 | 2010 | 552 | 0.070 |
Why?
| | Decompression, Surgical | 1 | 2007 | 106 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 820 | 0.070 |
Why?
| | Incidental Findings | 1 | 2007 | 87 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2010 | 294 | 0.070 |
Why?
| | Prednisone | 1 | 2007 | 240 | 0.060 |
Why?
| | Iris Neoplasms | 1 | 2006 | 1 | 0.060 |
Why?
| | Lymph Node Excision | 1 | 2007 | 171 | 0.060 |
Why?
| | Tacrolimus | 1 | 2007 | 199 | 0.060 |
Why?
| | Diagnostic Techniques, Digestive System | 1 | 2006 | 12 | 0.060 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2006 | 8 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2006 | 48 | 0.060 |
Why?
| | Treatment Failure | 1 | 2007 | 356 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 153 | 0.060 |
Why?
| | Weight Gain | 1 | 2009 | 519 | 0.060 |
Why?
| | Sirolimus | 1 | 2007 | 276 | 0.060 |
Why?
| | Walking | 1 | 2010 | 529 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2828 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2006 | 57 | 0.060 |
Why?
| | Alemtuzumab | 3 | 2010 | 15 | 0.060 |
Why?
| | DNA Damage | 2 | 1999 | 420 | 0.060 |
Why?
| | Polyethylene Glycols | 1 | 2010 | 641 | 0.060 |
Why?
| | Digestive System Surgical Procedures | 1 | 2006 | 106 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3566 | 0.060 |
Why?
| | Biopsy | 3 | 2016 | 1129 | 0.060 |
Why?
| | Mice | 2 | 2020 | 17787 | 0.050 |
Why?
| | HIV | 1 | 2025 | 234 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2010 | 2531 | 0.050 |
Why?
| | Adenoma | 1 | 2006 | 230 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1389 | 0.050 |
Why?
| | Shock, Septic | 1 | 2005 | 219 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2024 | 216 | 0.050 |
Why?
| | Animals | 3 | 2024 | 36940 | 0.050 |
Why?
| | Informatics | 1 | 2022 | 6 | 0.050 |
Why?
| | Cell Separation | 1 | 2023 | 318 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2189 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 512 | 0.040 |
Why?
| | Prospective Studies | 3 | 2022 | 7604 | 0.040 |
Why?
| | Necrosis | 1 | 2022 | 246 | 0.040 |
Why?
| | Quality of Life | 2 | 2010 | 2892 | 0.040 |
Why?
| | Mortality | 1 | 2022 | 362 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2010 | 804 | 0.040 |
Why?
| | Observer Variation | 1 | 2020 | 343 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 131 | 0.040 |
Why?
| | Plasmids | 2 | 1997 | 363 | 0.040 |
Why?
| | Cyclins | 1 | 1999 | 91 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2837 | 0.040 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 86 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2023 | 561 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 92 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2023 | 4193 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2009 | 132 | 0.040 |
Why?
| | Communication | 1 | 2024 | 879 | 0.040 |
Why?
| | Allografts | 1 | 2018 | 146 | 0.040 |
Why?
| | Rituximab | 2 | 2009 | 176 | 0.040 |
Why?
| | Cholangiography | 1 | 2016 | 17 | 0.030 |
Why?
| | Flow Cytometry | 2 | 1999 | 1178 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2016 | 39 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 198 | 0.030 |
Why?
| | Child, Preschool | 2 | 2013 | 11074 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 1997 | 164 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 466 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1066 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.030 |
Why?
| | Ataxia Telangiectasia | 1 | 1996 | 20 | 0.030 |
Why?
| | Cinnamates | 1 | 1996 | 10 | 0.030 |
Why?
| | Cell Cycle | 1 | 1999 | 601 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 2 | 2010 | 565 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2015 | 39 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 1999 | 648 | 0.030 |
Why?
| | alpha-Glucosidases | 1 | 2015 | 9 | 0.030 |
Why?
| | Fibroblasts | 2 | 1999 | 996 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 955 | 0.030 |
Why?
| | Curriculum | 1 | 2022 | 992 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 1997 | 327 | 0.030 |
Why?
| | Heart | 1 | 2018 | 655 | 0.030 |
Why?
| | Blotting, Western | 1 | 1997 | 1226 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1999 | 712 | 0.030 |
Why?
| | DNA Repair | 1 | 1996 | 231 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 554 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2010 | 3715 | 0.030 |
Why?
| | Infant | 1 | 2007 | 9465 | 0.020 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2013 | 38 | 0.020 |
Why?
| | Hepatoblastoma | 1 | 2013 | 46 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1483 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 1946 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2012 | 148 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2012 | 157 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1999 | 1502 | 0.020 |
Why?
| | Biomarkers | 2 | 2015 | 4149 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 2010 | 1353 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2013 | 510 | 0.020 |
Why?
| | Arizona | 1 | 2010 | 81 | 0.020 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2012 | 213 | 0.020 |
Why?
| | Ribavirin | 1 | 2010 | 91 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 5742 | 0.020 |
Why?
| | Blood Glucose | 2 | 2010 | 2186 | 0.020 |
Why?
| | Medical History Taking | 1 | 2009 | 117 | 0.020 |
Why?
| | Ileus | 1 | 2009 | 12 | 0.020 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 24 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | DNA | 1 | 1996 | 1459 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2992 | 0.020 |
Why?
| | Bortezomib | 1 | 2009 | 54 | 0.020 |
Why?
| | Bile Ducts | 1 | 2009 | 71 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 126 | 0.020 |
Why?
| | Hematologic Diseases | 1 | 2009 | 62 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 889 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 189 | 0.020 |
Why?
| | Prosthesis-Related Infections | 1 | 2009 | 95 | 0.020 |
Why?
| | Poisoning | 1 | 2009 | 120 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 665 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 683 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1062 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2009 | 227 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1007 | 0.020 |
Why?
| | Radiotherapy, Conformal | 1 | 2007 | 70 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2009 | 184 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 656 | 0.020 |
Why?
| | Hepatic Artery | 1 | 2006 | 62 | 0.020 |
Why?
| | Microsurgery | 1 | 2006 | 75 | 0.020 |
Why?
| | Angiography | 1 | 2006 | 207 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2031 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 806 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2006 | 166 | 0.010 |
Why?
| | Logistic Models | 1 | 2010 | 2074 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1916 | 0.010 |
Why?
| | Safety | 1 | 2006 | 338 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1710 | 0.010 |
Why?
| | Cause of Death | 1 | 2006 | 434 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2007 | 350 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3295 | 0.010 |
Why?
| | Prevalence | 1 | 2009 | 2734 | 0.010 |
Why?
| | Neoplasms | 1 | 1997 | 2671 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2006 | 625 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2389 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 6763 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 1999 | 17 | 0.010 |
Why?
| | Infrared Rays | 1 | 1999 | 25 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1587 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 65 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 121 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 1999 | 232 | 0.010 |
Why?
| | Mice, SCID | 1 | 1999 | 367 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2111 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 1999 | 378 | 0.010 |
Why?
| | Hygromycin B | 1 | 1996 | 3 | 0.010 |
Why?
| | Pentosyltransferases | 1 | 1996 | 5 | 0.010 |
Why?
| | Simian virus 40 | 1 | 1996 | 24 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1996 | 77 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2129 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1996 | 145 | 0.010 |
Why?
| | Cell Nucleus | 1 | 1999 | 620 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1996 | 183 | 0.010 |
Why?
| | Transfection | 1 | 1996 | 945 | 0.010 |
Why?
| | Cell Line | 1 | 1996 | 2847 | 0.010 |
Why?
|
|
Mekeel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|